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Abstract
Rationale:Human leukocyte antigen (HLA) is the major immunologic barrier in kidney transplantation (KT). Various desensitization
protocols to overcome the HLA barrier have increased the opportunity for transplantation in sensitized patients. In addition,
technological advances in solid-phase assays have permitted more comprehensive assessment of donor-speciﬁc antibodies.
Although various desensitization therapies and immunologic techniques have been developed, the ﬁnal transplantation decision is still
based on the classic complement-dependent cytotoxicity (CDC) crossmatch (XM) technique. Some patients who fail to achieve
negative XM have lost their transplant opportunities, even after receiving sufﬁcient desensitization therapies.
Patient concerns: A 57-year-old male with end-stage renal disease secondary to chronic glomerulonephritis was scheduled to
have a second transplant from his son, but CDC XM was positive.
Diagnoses: Initial CDC XM (Initial T-AHG 1:32) and ﬂow-cytometry XM were positive. Anti-HLA-B59 donor speciﬁc antibody was
detected by Luminex single antigen assay.
Interventions:Herein, we report a successful case of KT across a positive CDC XM (T-AHG 1:8 at the time of transplantation) by
using C1q assay-directed, bortezomib-assisted desensitization. After conﬁrming a negative conversion in the C1q donor-speciﬁc
antibody, we decided to perform KT accepting a positive AHG-CDC XM of 1:8 at the time of transplantation.
Outcomes: The posttransplant course was uneventful and a protocol biopsy at 3 months showed no evidence of rejection. The
patient had excellent graft function at 12 months posttransplant.
Lessons: The results of XM test and solid-phase assay should be interpreted in the context of the individual patient.
Abbreviations: AHG = anti-human globulin, CDC = complement-dependent cytotoxicity, DSA = donor-speciﬁc antibodies,
DTT = dithiothreitol, HLA = human leukocyte antigen, IVIG = intravenous immunoglobulin, KT = kidney transplantation, MFI =mean
ﬂuorescence intensity, NIH = National Institute of Health, PP = plasmapheresis, XM = crossmatch.
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11. Introduction
The presence of donor-speciﬁc antibodies (DSA) has been
considered a contraindication for renal transplantation, as
such its presence has been associated with hyperacute
rejection and immediate graft loss.[1] A complement-depen-
dent cytotoxicity (CDC) crossmatch (XM) was developed to
identify DSA directed against donor lymphocytes, which are
associated with hyperacute rejection. Consequently, various
XM techniques were introduced to enhance test sensitivity.
Furthermore, application of a solid-phase test for DSA has
allowed detection and characterization of the relevant anti-
bodies.[2,3]
With recent advances in immunologic tests, desensitization
protocols to overcome the human leukocyte antigen (HLA)
barrier have increased the opportunity for transplantation in
sensitized patients with renal failure.[4,5] New interventions, such
as bortezomib, are used for desensitization under the expectation
of increasing transplantability.[6] However, decisions to perform
kidney transplantation (KT) after desensitization were based on
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Figure 1. Desensitization protocol and trends in DSA. AHG=anti-human
globulin, ATG=anti-thymocyte globulin, CDC XM=complement-dependent
cytotoxicity crossmatch, DSA=donor-speciﬁc antibodies, IVIG= intravenous
immunoglobulin, KT=kidney transplantation, MFI=mean ﬂuorescent intensity,
PP=plasmapheresis.
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phase tests or new interventions.
In this study, we report a successful KT across a positive CDC
XM (1:8 T anti-human globulin [AHG]) at the time of
transplantation. After receiving a desensitization protocol
comprising plasmapheresis (PP), intravenous immunoglobulin
(IVIG), rituximab, and bortezomib, the patient’s C1q-positive
antibodies were converted to C1q-negative status.
2. Case review
A 57-year-old male with end-stage renal disease secondary to
chronic glomerulonephritis underwent his ﬁrst KT from his
brother in 1996. He lost the allograft due to chronic rejection and
returned to hemodialysis in 2011. He was scheduled to have a
second transplant in another center from either his two sons or
his wife, but all were CDC XM positive. A desensitization
protocol using high-dose IVIG failed to achieve a negative CDC
XMwith his donors. Subsequently, he was put on the waiting list
for 4 years and offered kidneys twice. However, neither time heTable 1
Changes in SABA IgG and SABA C1q assays after desensitization.
Informative epitopes based on
donor-speciﬁc epitope reaction
∗
Pre-desensitizat
SABA IgG
69TNT Positive
66IF+163TEW Positive
80I+65QI Positive
131s+163T Positive
163TEW+65QI Positive
45EE Positive
62RNQ Positive
66IF Positive
71TTN Positive
94TW Positive
97T Positive
113HN Positive
116L Negative
NIH-CDC-XM Positive (1:1)
AHG-CDC-XM Positive (1:32)
AHG= anti-human globulin, CDC= complement-dependent cytotoxicity, NIH=National Institute of Health
∗
Epitope reactions were analyzed using HLA matchmaker (HLA-ABC antibody analysis [v02] updated on Jun
(http://www.epregistry.ufpi.br/).
2could undergo KT because he revealed positive CDC XM
reactions to the 2 deceased donors. He was then referred to our
center for second living donor (from his older son) KT.
The donor and recipient were mismatched on 2 HLA loci
(donor A2,33; B58,59; DR4,13 and recipient A33,33; B46,58;
DR4,13). Initial CDC XM (National Institute of Health [NIH]-T
cell-CDC XM 1:1 and AHG-T cell-CDC XM 1:32) and ﬂow-
cytometry XM were positive. Dithiothreitol (DTT) treated
patient sera (ﬁnal DTT concentration of 0.005M) were used
for CDC and ﬂow-cytometry XM. Pronase-treated donor
lymphocytes were used for ﬂow-cytometry XM. Anti-HLA-
B59 DSA was detected by Luminex single antigen assay
(LABScreen SAB Class I and Class II; One Lambda, Canoga
Park, CA) with a mean ﬂuorescence intensity (MFI) of 16,584
and by C1q assay. His calculated panel reactive antibody with
levels above 1000MFI was 97.9%.We planned a desensitization
protocol comprising a single dose of rituximab (375mg/m2), PP
followed by IVIG (100mg/kg/d), and bortezomib (Fig. 1).
Tacrolimus (target trough level: 3–8ng/mL) was started 1 week
before transplantation. Induction therapy with anti-thymocyte
globulin at a dose of 1.5mg/kg/d was initiated at operation day
and continued for 5 days after transplantation.
After 2 sessions of PP + IVIG, the MFI value of the DSA was
still >10,000 and the C1q DSA result was positive. The
patient received 1 cycle of bortezomib (1.3mg/m2, on days 1,
4, 8, and 11) along with further PP + IVIG treatment.
Although the MFI value of the DSA remained over 10,000, the
C1q DSA result became negative. Changes in antibodies
against donor-speciﬁc epitopes are presented in Table 1.
Three-dimensional HLA models demonstrated that desensiti-
zation had a different effect on epitope reaction between IgG
and C1q assays (Fig. 2).
After conﬁrming a negative C1q-binding DSA, we decided to
perform KT accepting a positive AHG-CDC XM of 1:8 at the
time of transplantation. The kidney appeared well perfused and
did not show evidence of hyperacute rejection.
The patient did not receive posttransplant PP + IVIG treatment,
and his postoperative course was uneventful. The protocol biopsy
performed at postoperative month 3 showed mild tubular
dilatation with a few casts. Peritubular C4d staining was negativeion Post-desensitization
SABA C1q SABA IgG SABA C1q
Positive Positive Negative
Positive Positive Negative
Positive Positive Positive
Positive Positive Negative
Positive Positive Negative
Positive Positive Negative
Negative Positive Negative
Positive Positive Positive
Positive Positive Negative
Positive Positive Positive
Positive Positive Positive
Positive Positive Positive
Positive Negative Negative
Negative
Positive (1:8)
, SABA= single antigen-bead assay, XM=crossmatch.
e 2016, http://www.epitopes.net/) and informative epitopes are deﬁned based on HLA epitope registry
Figure 2. Three-dimensional HLA models with immunogenic epitopes. (A) Multiple donor-speciﬁc epitope reactions were positive in IgG assay at pre- and post-
desensitization. (B) Donor-speciﬁc epitope reactions in the C1q assay prior to desensitization. (C) Donor-speciﬁc epitope reactions in the C1q assay after
desensitization. Pink: alpha domain, blue: beta domain, brown: peptide, yellow: reactive donor-speciﬁc epitopes. Residue locations deﬁning epitopes on the HLA
molecular surface were visualized using the Cn3D structure and sequence alignment software program (downloaded from https://www.ncbi.nlm.nih.gov/
Structure/CN3D/cn3d.html).
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peritubular capillary changes were present on examination via
electron microscopy. Additional kidney injury molecule-1
immunohistochemistry for the evaluation of acute tubular injury
showed negative staining in proximal tubules (Fig. 3). Currently,
at 12 months post-transplantation, the patient continues to do
well with a baseline creatinine level of 1.0mg/dL and a urinary
protein-to-creatinine ratio of less than 0.1 (g/gCr). Anti-HLA-
B59 DSA remains at MFI 7815, but no HLA antibody reaction
has been detected by C1q assay. The patient did not suffer acute
rejection or infectious complication during follow-up.
The study procedures were in accordance with the Declaration
of Helsinki. All procedures were performed after obtaining
informed consent. A single patient case report does not require
institutional review board approval according to our board
policy.3. Discussion
Historically, several cases of transplantation with a positive CDC
XM at transplantation were performed in the past prior to the
introduction of solid-phase tests or new interventions.[4,7] In
those cases, most patients had poor outcomes, but some cases did
have acceptable outcomes. The reasons for the different courses
remain unknown, but a positive CDC XM is a contraindication
to transplantation. Afterward, despite advances in desensitiza-Figure 3. Protocol biopsy. (A) Renal structure is well preserved without glomerulit
intact and do not show positivity with kidney injury molecule-1 immunohistochem
3tion protocols and immunologic testing, most KTs are performed
after achievement of a negative CDC XM. In this report, we
present a successful case of KT with a persistently positive CDC
XM (T-AHG 1:8 at the time of transplantation) following C1q
assay-directed, bortezomib-assisted desensitization.
KT is the treatment of choice for end-stage renal disease
patients. However, over 30% of patients on a waiting list are
sensitized to HLA due to pregnancy, blood transfusion, or
previous transplantation. These sensitized patients are less likely
to ﬁnd compatible deceased donors and thus have a prolonged
waiting time. In addition, they have a limited possibility of
undergoing a paired kidney exchange.[8] Desensitization proto-
cols to overcome the HLA barrier have become increasingly
popular because of organ shortages and have increased the
opportunity for transplantation in sensitized patients.[4,5,9]
Despite a low incidence of hyperacute rejection and acceptable
short-term outcomes in sensitized patients, antibody-mediated
rejection remains a signiﬁcant challenge even after successful
desensitization.[10] Concern that relevant DSA are not being
detected by less sensitive assays has led to the development of
more sensitive XM techniques. Paradoxically, CDCXMhas been
used as a minimum requirement for KT due to its low
sensitivity.[11] However, recent studies have demonstrated that
KT recipients from HLA incompatible donors exhibit a
substantial survival beneﬁt compared to that in patients who
did not undergo transplantation and those who waited foris or tubulointerstitial inﬂammation (Periodic acid-Schiff, 100). (B) Tubules are
ical staining (KIM-1, 100).
[12]
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Therefore, accurate analysis of an individual’s DSA, which helps
in the decision on whether to proceed with a transplantation, is
critical for a patient.
Although the development of solid-phase assays has greatly
elucidated the role of DSA in the immune response to allografts, it
is difﬁcult to determine an MFI cutoff value suitable for
proceeding to transplantation.[13] In fact, MFI values determined
with conventional solid-phase assays do not accurately correlate
with the complement-binding DSA. In contrast, the C1q assay
directly discriminates the ability of a particular complement-
binding DSA. It is quite important in a clinical setting considering
that the DSA mediated complement cascade is the hallmark of in
vivo graft injury.[14] The classic CDC XM is neither sensitive nor
speciﬁc enough to detect complement ﬁxation.[15,16] In our case,
the AHG-CDC-XM result was 1:8 positive, but the NIH-CDC-
XM and C1q DSA results were negative at KT. Hence, we
decided to perform KT considering not only the CDC XM
indicators, but also the results of the solid-phase tests. To the best
of our knowledge, this is the ﬁrst report of successful KT
following C1q assay-directed desensitization.
Desensitization protocols have been based on PP and/or IVIG,
which physically remove or inhibit the circulating DSA. In
addition, rituximab is widely used for reducing B-cells.[4,9]
Nevertheless, prior desensitization protocols have demonstrated
varying degrees of efﬁcacy and durability. A potential explana-
tion for the variation among results is the failure to inhibit plasma
cells, the source of antibodies.[6]
Bortezomib, a proteasome inhibitor, exerts an inhibitory effect
directly on antibody-secreting plasma cells. Prior study using
bortezomib-based desensitization represented a signiﬁcant and
sustained reduction in DSA, which may allow for increased
transplantability.[6] We achieved a negative C1q conversion in
this highly sensitized patient by using bortezomib as an additional
therapy. In addition, the patient did not suffer clinical rejection in
the absence of postoperative PP and IVIG. The protocol biopsy
also demonstrated no evidence of subclinical rejection.
Interestingly, the patient showed positive AHG-CDC XM
without C1q-binding DSA. Therapeutic agents used in desensiti-
zation protocols have been shown to cause interference in XM
results.[17] In our case, however, the positive CDC XM is hard to
be deemed a false positive considering the highMFI of DSA at the
time of transplantation. Rather, epitope analysis can provide a
possible explanation for the positive CDCXM reaction. Epitopes
are parts of an antigen recognized by antibodies. As epitope
reaction depends on the 3-dimensional structure, changes in this
structure may lead to changes in the antibody reactivity.[18] If
there is an insufﬁcient conformational area due to a structural
change, even though some C1q epitope reactions were positive,
but overall C1q DSA could be negative. After the desensitization,
the HLA-B59 DSA itself turned into negative in the C1q assay,
but multiple donor-speciﬁc epitope reactions remained positive in
the IgG assay with several epitope reactions in the C1q assay.
These complement-binding antibodies against donor-speciﬁc
epitopes with high concentrations of noncomplement-binding
antibodies might induce a positive AHG-CDC XM reaction even
after desensitization.4In conclusion, we report a successful KT across a positive CDC
XM at the time of transplantation, by using C1q assay-directed,
bortezomib-assisted desensitization. The goal of desensitization is
to maximize the opportunity for transplantation, with improved
mortality and quality of life compared with that associated with
dialysis. However, for over 40 years, transplantation decision
making has been based on the CDC XM, regardless of the
presence of more sensitive and more accurate immunologic tests.
The cost of continuing the historical approach is that of
eliminating some patients that could have undergone a successful
transplant. Therefore, the results of XM tests and solid-phase
assays must be interpreted in the context of the individual patient.
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